New York Eye and Ear Infirmary
Adjust: Text Size Make Font Smaller Make Font Larger Print this Page: Normal Print Friendly Large Print Friendly Accessibility Info

The EYEGUARD-A study

A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis

This study is currently recruiting participants.

Purpose: The primary objective of this study is to demonstrate the superiority of gevokizumab (at least one of the two doses) compared to placebo in the treatment of subjects with active non-infectious intermediate, posterior, or pan- uveitis. In addition, the safety of gevokizumab will be assessed.

Eligibility:

  • Male or female, age > or = to 18 years old with Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
  • Uveitis disease, defined by the presence of ≥ 2+ vitreous haze score in at least one eye (SUN/NEI criteria).

Contact Information

C. Michael Samson, MD, Uveitis Specialist

Alex Yang, Clinical Research Coordinator at (212) 979-4024
or ayang@nyee.edu

 

Home > Current Research > Clinical Trials in Ophthalmology >A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis